NPS Pharmaceuticals (NPSP +7.6%) moves up on a 2.5x surge in volume. Investors' interest has been stoked after the Wall Street Journal reported that Goldman Sachs was putting feelers out about a possible acquisition. Shire plc is one candidate in light of its failed marriage with AbbVie.
Separately, the extended PDUFA date for the FDA's review of the company's BLA for Natpara for the treatment of hypoparathyroidism is January 24. Since this is a Saturday, the agency may issue its decision on Friday the 23rd. On September 12, the FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 8-5 in favor of approval.
Previously: FDA extends Natpara PDUFA date (Oct. 23, 2014)
Previously: Positive Ad Comm vote for Natpara (Sept. 12, 2014)